About Okyanos
Okyanos is a Healthcare company based in Freeport (Bahamas) founded in 2011, and was acquired by Black Beret Life Sciences in July 2017. Provider of medical treatments in regenerative medicine. Okyanos has raised $8.9 million across 1 funding round from investors including Black Beret Life Sciences. Its chief executive, as recorded, is Vincent Burton. Okyanos offers products and services including Stem Cell Therapy and Enzyme-Derived SVF. Its focus areas include Services for Healthcare Providers and Continuing Medical Education.
Company details
Okyanos was founded in 2011 and is based in Freeport, Bahamas. Operations focus on regenerative medicine, where adult stem cell therapies are provided for conditions including neurological, orthopedic, cardiac, autoimmune, and COPD. Partnerships with universities and research labs are maintained to collect data on stem cell applications. Educational videos and papers on the subject are also made available.
- Headquarters Freeport, Bahamas
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website okyanos.com/vi
- Social LinkedIn X Facebook
- Acquired by Black Beret Life Sciences (Jul 2017)
- Total Equity Funding$8.9M (USD)
in 1 rounds
- Latest Funding Round$8.9M (USD), Series B
Mar 2014
- Investors
- Acquired byBlack Beret Life Sciences
(Jul 2017)
Products & Services of Okyanos
Okyanos offers a comprehensive portfolio of products and services, including Stem Cell Therapy and Enzyme-Derived SVF.
Uses stem cells to treat injuries and chronic conditions effectively.
Processes enzymes to derive SVF for therapeutic applications.
Funding Insights of Okyanos
Okyanos has successfully raised a total of $8.9M through 1 strategic funding round. The most recent funding activity was a Series B round of $8.9 million completed in March 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.9M
- Total Rounds 1
- Last Round Series B — $8.9M
- First Round $8.9M
(Mar 2014)
All 1 funding rounds of Okyanos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2014 | $8.9M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in Okyanos
Okyanos has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Black Beret Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| bbls.net |
Investor details for Okyanos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Okyanos
1 people are tracked at Okyanos (1 in leadership).
| Name | Role | Group |
|---|---|---|
Vincent Burton | CEO & President | Leadership |
Complete people profiles for Okyanos
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Okyanos
3 dated milestones of Okyanos across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Okyanos is founded.
- Funding First funding round of $8.9M.
- Exit Acquired by Black Beret Life Sciences.
Web traffic of Okyanos
The website of Okyanos (okyanos.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 2.2% vs previous month
Websites whose visitors overlap most with Okyanos. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
health-tourism.com | health-tourism.com | 100% | #465,579 | – | |
regenexx.com | regenexx.com | 100% | #437,238 | – | |
nurseslabs.com | nurseslabs.com | 100% | #116,676 | – | |
onhealth.com | onhealth.com | 100% | – | ||
| medtronic.com | 100% | 2.6M | #22,622 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 23 similar websites and full traffic analytics for Okyanos
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 23 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Okyanos
Okyanos was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Okyanos is headquartered in Freeport, Bahamas.
Vincent Burton is the CEO of Okyanos, as recorded in our data.
Okyanos is a funded company, having raised a total of $8.9M across 1 funding round to date. The company's 1st funding round was a Series B of $8.9M, raised on Mar 2014.
Okyanos was founded in 2011 and is based in Freeport, Bahamas. Operations focus on regenerative medicine, where adult stem cell therapies are provided for conditions including neurological, orthopedic, cardiac, autoimmune, and COPD. Partnerships with universities and research labs are maintained to collect data on stem cell applications. Educational videos and papers on the subject are also made available.
Okyanos offers Stem Cell Therapy and Enzyme-Derived SVF.
Okyanos has 1 investor. Key investors include Black Beret Life Sciences.
Yes. Okyanos was acquired by Black Beret Life Sciences in July 2017.